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Abstract
Item response theory (IRT) has been recently adopted to successfully characterize the 
progression of Parkinson's disease using serial Unified Parkinson's Disease Rating 
Scale (UPDRS) measurements. However, it has yet to be applied in predicting the 
longitudinal changes of levodopa dose requirements in the real- world setting. Here 
we use IRT to extract two latent variables that represent tremor and non- tremor- 
related symptoms from baseline assessments of UPDRS Part III scores. We show that 
relative magnitudes of the two latent variables are strong predictors of the progressive 
increase of levodopa equivalent dose (LED). Retrospectively collected item- level 
UPDRS Part III scores and longitudinal records of prescribed medication doses of 
128 patients with de novo PD extracted from the electronic medical records were used 
for model building. Supplementary analysis based on a subset of 36 patients with at 
least three serial assessments of UPDRS Part III scores suggested that the two latent 
variables progress at significantly different rates. A web application was developed 
to facilitate the use of our model in making individualized predictions of future LED 
and disease progression.
STUDY HIGHLIGHTS
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
The rate of disease progression and treatment responses differ substantially between 
rigidity and tremor- dominant motor subtypes. Currently, little is known about how 
levodopa dose requirements change with disease progression in the real- world setting.
WHAT QUESTION DID THIS STUDY ADDRESS?
By applying item response theory modeling framework, we investigated whether ini-
tial and future trajectories of levodopa equivalent dose (LED) could be predicted at 
the time of initial diagnosis using baseline UPDRS Part III measurements and patient 
covariates.
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INTRODUCTION
Parkinson's disease (PD) is widely assessed using the Unified 
Parkinson's Disease Rating Scale (UPDRS).1 The UPDRS is 
composed of four parts with subscores of Part III assessing 
the motor symptoms. The sum of the item scores is gener-
ally used to track the progression of disease status. However, 
the implicit assumption of all items progressing at a more or 
less similar rate is being increasingly challenged.2 To address 
the heterogeneous nature of the UPDRS score items, various 
methods have been used to identify distinct symptom clusters.
Item response theory (IRT) is a popular paradigm tradi-
tionally used in psychometrics to design, analyze, and score 
psychological tests and questionnaires. The core assumption 
is that each item score is a manifestation of the underlying 
latent ability or trait. Because certain items are easier to score 
than others, item difficulty is a core parameter of the IRT 
model. Items also differ in their discrimination, that is, some 
items more sensitively reflect the difference in the underlying 
ability than others.
Pharmaceutical and medical researchers are increasingly 
adopting IRT to analyze composite scores used for medi-
cal diagnosis, such as the Alzheimer's Disease Assessment 
Scale– Cognitive subscale3 and others.4– 7 It has been success-
fully applied to modeling UPDRS progression in patients 
with PD as well.8– 10 When used in these contexts, latent abil-
ity or trait is often interpreted as latent disease severity. Item 
difficulty and discrimination then determine the probability 
of observing a particular symptom severity given the overall 
disease severity.
Levodopa remains the most effective drug for treat-
ing PD.11 However, the progression of PD accompanies a 
concomitant increase in daily levodopa dose requirements. 
Because higher doses of levodopa lead to various motor 
complications12 and a “wearing- off” phenomenon,13 accu-
rately predicting the rate of such increase and elucidating the 
sources of its interindividual variability will help better op-
timize treatment and clinical trials targeting different stages 
of PD.
In practice, levodopa is only one of the possible treatment 
strategies. Alternative strategies include dopamine agonists, 
a monoamine oxidase type B inhibitor, and a catechol- O 
methyl transferase inhibitor, calling for the need of a common 
scale to compare their effectiveness. The levodopa equivalent 
dose (LED) is defined as the dose yielding the same anti-
parkinsonian effects as 100 mg levodopa. Different formulae 
for calculating LEDs have been initially proposed that were 
subsequently standardized through meta- analysis.12 The most 
recent proposal of LED conversion factors includes opica-
pone and safinamide.14
Here we apply IRT to baseline UPDRS Part III scores 
to extract two independent latent variables representative 
of tremor and nontremor symptoms. We then develop a 
model to predict the longitudinal trajectories of LED after 
treatment initiation under a nonlinear mixed effects frame-
work.15 We show how the rate of LED increase can be better 
predicted using these latent variables. As a supplementary 
analysis, we calculate the expected progression of the two 
latent variables over time based on a subset of patients with 
serial UPDRS Part III measurements. To facilitate the use of 
our model, we developed a web application that can be used 
to generate individualized predictions of LED and UPDRS 
Part III scores.
METHODS
Inclusion/exclusion criteria and study end 
points
This retrospective study included 128 patients with de 
novo PD who visited the outpatient clinic of the Neurology 
Department of Severance Hospital, Seoul, Korea, between 
March 2009 and October 2016. The institutional review board 
and hospital research ethics committee (Yonsei University 
Health system) approved this study and waived patient con-
sent because of its retrospective character.
Information collected from the electronic medical record 
(EMR) included the following:
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
The relative magnitudes of the two latent variables estimated from the baseline as-
sessment of UPDRS Part III, in addition to patient age, provide crucial information 
to predict the adequate initial LED and its future trajectories in an individual patient.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
Our study offers a novel method that allows effective prediction of future LED re-
quirements based on a one- time assessment of UDPRS Part III scores and patient co-
variates. The results of our work would be useful in determining the right LED based 
on a patient’s disease status and minimizing the need for empirical dose titrations.
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1. Basic demographic factors: age, sex
2. Medical history: hypertension, diabetes mellitus
3. Mini- Mental Status Examination and Beck Depression 
Inventory assessed at the time of initial diagnosis
4. Item level UPDRS Part III scores assessed at the time of 
initial diagnosis and subsequent follow- up visits
5. Dose amounts converted to LED prescribed during the ob-
servation period
Table 1 summarizes the collected data.
The study end points were the subscores of the UPDRS 
Part III items and LEDs calculated from the prescription re-
cords, whose definitions are given in Table S1.
Modeling the increase of LED with time
To mimic the gradual increase in LED with disease pro-
gression, we fitted the following model to serial LED 
measurements:
where LED0 is the initial LED, LEDmax is the maximum LED 
allowed for prescription, and r is the rate of LED escalation.
An asymptotic exponential function (i.e., 1– e−rt) was used 
to describe the nonlinear increase of LED toward the maxi-
mum level. A simpler model assuming a linear increase of 
LED with time (i.e., rt) was not used because it allows bound-
less increases of LED.
Latent variables
Degeneration of dopamine neurons in the substantia nigra 
is known to be primarily responsible for the pathogenesis of 
PD.16 The severity of bradykinesia and rigidity strongly cor-
relates with the degree of dopamine depletion, but the severity 
of tremor does not show such correlation.17 Based on this prior 
knowledge, we hypothesized that the variability associated with 
PD symptoms was caused by two independent dimensions, 
each of which represents tremor and nontremor symptoms.
To support this hypothesis, we performed principal com-
ponents analysis and hierarchical clustering on the baseline 
UPDRS Part III items.
Item response models
Baseline model development
Let yj, j = 18,…, 31 denote the score of 14 items with j corre-
sponding to the UPDRS Part III item, as shown in Table S1. 
The probability (P) of item score yj being greater than or 
equal to some integer n is expressed as follows:
where aj is the discrimination; bjn is the difficulty; jmax = 20 for 
j = 20 and 22; jmax = 8 for j = 21, 23– 26 and jmax = 4 otherwise; 
P(yj ≥0) = 1; and P(yj = jmax) = P(yj ≥ jmax).
Items associated with higher aj can better discriminate 
small differences in disease severity. Items with higher bjn 
require higher disease severity, S, to attain the same score. In 
this work, we did not estimate a separate difficulty parameter 
for each of the items because this would lead to a prolifera-
tion of parameters that far exceeds the data capacity. Instead, 
we introduced a threshold difficulty of achieving the mini-
mum score of 1 and an incremental difficulty needed for each 
additional score. Denoting the threshold difficulty associated 
with item j as bj,1 and incremental difficulty as bj,inc, Equation 
(2) can be modified to:
(1)LED(t) = LED0 + (LEDmax − LED0) ⋅ (1 − e− rt)
(2)P(yj ≥ n) =
1
1 + e−aj(S−bjn)
n = 1, 2, 3, jmax
(3)
P(yj = n) = P(yj ≥ n) − P(yj ≥ n + 1) n = 0, 1, 2, 3, jmax − 1
(4)P(yj ≥ n) =
1
1 + e−aj(S−bj,1 − (n−1)bj,inc)
T A B L E  1  Descriptive statistics of collected data items
Covariates Mean (SD) or n (%)
Continuous
Age, years 61.07 (9.27)
Baseline UPDRS Part III score 23.19 (10.56)
CCSIT 7.10 (2.45)
MMSE 26.48 (2.81)
Beck Depression Inventory 14.81 (9.60)
Presence of diabetes mellitus 18 (14.17%)
Presence of hypertension 38 (29.92%)











Abbreviations: CCSIT, Cross- Cultural Smell Identification Test; LED, levodopa 
equivalent dose; MMSE, Mini- Mental State Examination; UPDRS, Unified 
Parkinson's Disease Rating Scale.
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In accordance with the standard IRT modeling approach, 
we assumed that S follows a standard normal distribution. We 
then used baseline UPDRS Part III scores to fit the model. 
Hereafter, we use the notations Strem and Snontrem to represent 
the latent variables associated with tremor and nontremor 
symptom dimensions, respectively.
Covariate search
Covariate influence on the model parameter was tested using 
the following formulations: 
 
 
Equation (5) imposes a linear relationship between the 
covariate and the parameter, whereas Equation (6) assumes 
a log- linear relationship between the two. In both Equations 
(5) and (6), TVPar denotes the typical (or population) value 
of a parameter; COV and MED the covariate and median co-
variate, respectively; θ1 the TVPar evaluated at the median 
covariate; and θ2 the TVPar increment on the log scale for the 
unit increase of the covariate. Pari in Equation (7) denotes the 
parameter value for the ith individual and ηi an interindivid-
ual random difference distributed as N(0, ω2).
Covariate selection was based on a significant decline of 
residual sum of squares (p value <0.05).
Parameter estimation and model evaluation
NONMEM 7.418,19 was used for fitting the model and acquir-
ing maximum likelihood estimates of the parameters.
Evaluation of the LED prediction model was done by 
generating goodness- of- fit plots of observed LED versus 
predicted LED and examining whether the scattered points 
fell around the line of unity. As a quantitative measure, we 
regressed the observed LED on the predicted LED and as-
sessed the R2 statistics.
To evaluate the IRT model performance, we generated 
a random number, u, from a uniform distribution and com-
pared its value with P(yj ≥ n) (see Equation (2)) for n = 1, 
2, 3, jmax. If u > P(yj ≥ n) and u < P(yj ≥ n- 1), then ŷj = n, 
with ŷj denoting the simulated score. The distribution of ŷj 
was compared with that of the observed scores using mir-
ror plots.9 Scatterplots of observed versus median predicted 
proportions were additionally generated to help assist the 
overall goodness of fit.
To assess the correlation between residuals, we generated 
the expectations of the individual scores given the estimates 
of the latent variables, calculated as follows:
where yj, j = 18,..,31, denote the score of 14 items with j corre-
sponding to the UPDRS Part III item, and jmax = 20 for j = 20 
and 22; jmax = 8 for j = 21, 23– 26; and jmax = 4 otherwise. 
S = Strem for j = 20, 21 and S = Snontrem, otherwise. P(yj = i) was 
calculated based on Equation (3). We then generated a correla-
tion matrix of the residuals, yj – E(yj).
Item characteristic curves were generated for each item 
and superimposed on the loess curves of the observed data.
Web application development
R/Shiny20 was used to implement the developed model as 
an online web application. The UPDRS Part III scores may 
be either directly input using the application widgets or up-
loaded as a comma- separated file. The estimated severities 
of tremor and nontremor symptoms and future LED tra-
jectories are provided. The uncertainty associated with the 
estimated variables is also shown using profile likelihoods.
RESULTS
Modeling the longitudinal trajectories of LED
We fitted Equation (1) to the longitudinal measurements of 
LED under a nonlinear mixed effects modeling framework. The 
estimate of the rate of LED increase was 0.0025/month, sug-
gesting that a typical patient would take about 92 years (= four 
half- lives = 4 × log(2)
0.0025
) to reach the maximum LED of 2600 mg/
day. The mean LED prescribed at the time of initial diagno-
sis was 440 mg/day. Although there was restricted interpatient 
variability associated with the initial LED, the rate of LED esca-
lation showed significant differences among patients. The coef-
ficients of variation (CV) of the initial LED and the rate of LED 
escalation were 32.35% and 74.17%, respectively. We hereafter 
denote the base model without covariates as Model 1.
Post hoc analysis using the empirical Bayesian esti-
mates of the model parameters revealed a tendency of a 
higher initial LED in older age patients. On the other 
hand, the maximum LED seemed to negatively correlate 
with increasing age. The significance of these relation-
ships was tested by incorporating age as covariates into 
both initial and maximum LEDs. Comparing the estimated 
−2- log- likelihoods, commonly referred to as the objective 
function values (OFVs), of the models with and without 
(5)TVPar = 1 + 2(COV − MED)
(6)TVPar = 1 ⋅ exp(2(COV − MED))





n ⋅ P(yj = n)
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age as covariates returned a statistically significant differ-
ence (p = 1.78e- 07).
The following equations describe the relationship between 
age and LED0/ LEDmax:
We refer to the model incorporating age as covariates of 
LED0 and LEDmax as Model 2.
Principal components analysis and 
hierarchical clustering
Principal components analysis of baseline UPDRS Part 
III item scores showed that the first principal component, 
strongly correlated with nontremor items scores (all items ex-
cept 20 and 21), explained 46.6% of total variability, whereas 
the second principal component, correlated with tremor items 
(items 20 and 21), explained 11.5% of the total variation (see 
Figure 1a).
Hierarchical clustering returned a similar result where 
the highest branching point corresponded to the division of 
tremor (items 20/21) and nontremor symptoms (the rest of 
the items). Figure 1b depicts the dendrogram of the hierar-
chical clusters.
Item response model
IRT model was fitted using the pretreatment UPDRS Part 
III item scores from 126 patients, and the maximum like-
lihood estimates of the model parameters were acquired 
(Table 2a).
Among nontremor symptoms, items 25 (pronation- 
supination movements of hands) and 31 (bradykinesia) 
were among those associated with the lowest threshold 
difficulty levels. On the other hand, item 30 (postural 
(9)LED0 = 433 + 8.64 ⋅ (age − 60)
(10)LEDmax = 1990 − 47.4 ⋅ (age − 60)
F I G U R E  1  (a) Biplot generated by 
performing principal components analysis. 
(b) Dendrogram drawn by performing 
hierarchical clustering. PC1, principal 
component 1; PC2, principal component 2; 
UPDRS, Unified Parkinson's Disease Rating 
Scale
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instability) showed the highest threshold difficulty, fol-
lowed by item 27 (rising from chair). Among the tremor 
symptoms, item 21 (kinetic/postural tremor) was consis-
tently associated with a lower threshold difficulty than 
item 20 (resting tremor).
Joint modeling of longitudinal LED 
trajectories and baseline UPDRS Part III
To assess how the two latent variables, Strem and Snontrem, 
are related to the rate of increase of LED (r) and the in-
itial LED (LED0), we assessed the correlation of r and 
LED0, the estimated differences of individual r and LED0 
from the population mean, respectively, with Strem, Snontrem, 
Snontrem – Strem, and the baseline total UPDRS III score. The 
results are shown in Table S2 and Figure S1. The Pearson 
correlation coefficient between ηr and Snontrem – Strem was 
0.38 (p  =  9.77e- 06) and that between LED0 and Snontrem 
was 0.40 (p = 2.67e- 06).
Based on the previous results, we constructed a joint 
LED- UPDRS model by incorporating Strem – Snontrem as 
a covariate of r and Snontrem as a covariate of LED0. The 
OFV drop relative to the model incorporating only age 
was statistically significant (p = 4.94e- 10). The following 
equations describe the incorporated covariate– parameter 
relationships:
The full covariate model incorporating both age and latent 
variables as covariates is defined as Model 3. The parameter 
estimates of Model 3 are shown in Table 2b.
Model evaluation
The observed time trajectories of LED are shown in Figure 2a. 
The goodness- of- fit plots of the Models 1, 2, and 3 are shown 
in Figure 2b– d. The R2 statistics of the three models were 
0.24, 0.28, and 0.52, respectively.
Figure  3 shows the concordance of the observed and 
simulated scores using mirror plots. Most of the observed 
proportions fell within the 95% confidence intervals of the 
predicted proportions, with some items being better predicted 
than others. Item- wise scatterplots of observed and predicted 
proportions (Figure S2) revealed a wider scatter around the 
line of unity for items 21, 22, and 26.
Item characteristic curves of 14 UPDRS Part III items 
(Figure  S3) showed an overall good fit with the observed 
trends, although tremor- related items (items 20 and 21) 
showed a relatively poorer fit.
A Pearson correlation matrix (Figure S4), with correlation 
values ranging from −1 (indicated by blue) to +1 (indicated 
by red) revealed no distinct patterns, such as runs of positive 
or negative correlations or alternating positive and negative 
correlations.
(11)r = 0.0038 ⋅ exp(0.40 ⋅ (Snontrem − Strem))
(12)LED0 = 438 + 8.31 ⋅ (age − 60) + 51.84 ⋅ Snontrem
T A B L E  2  Maximum likelihood estimates of the models: (a) IRT 
model of baseline UPDRS Part III scores and (b) LED prediction 
model
(a) IRT model of baseline UPDRS Part III scores
Item
Item- related parameter (%RSE)
aj bj,1 bj,inc
18 1.14 (22.66) −0.58 (37.09) 2.95 (19.52)
19 1.19 (19.57) −1.07 (23.95) 3.15 (16.44)
20 1.43 (16.04) −0.60 (32.89) 0.65 (12.76)
21 1.13 (24.22) −1.17 (20.22) 0.89 (22.27)
22 1.26 (17.97) −1.97 (13.94) 0.50 (13.95)
23 1.70 (18.12) −1.76 (13.30) 1.01 (13.45)
24 2.06 (15.18) −1.31 (12.5) 1.05 (11.70)
25 1.94 (14.58) −1.84 (10.78) 0.96 (10.39)
26 2.27 (15.1) −2.27 (15.10) 0.84 (9.66)
27 2.19 (16.18) 0.32 (44.34) 1.64 (16.67)
28 1.10 (20.35) −1.19 (27.67) 2.16 (17.40)
29 1.46 (21.96) −1.42 (18.56) 3.17 (15.55)
30 1.24 (25.40) 1.12 (23.8) 1.75 (22.19)
31 2.21 (18.20) −1.86 (13.89) 2.07 (12.26)
(b) LED prediction model
Parameter Estimate (%RSE)
Fixed effects
LED0, mg 438.4 (3.36)
LEDmax, mg 2010 (14.49)
r, /month 0.0038 (22.91)
Covariate coefficients
Age on LED0, years 8.31 (17.96)
Age on LEDmax, years 45.8 (26.32)
Snontrem on LED0 51.84 (27.27)
Snontrem – Strem on r 0.40 (23.14)
Random effects
Interindividual variance of LED0, CV% 25.69 (11.95)
Interindividual variance of r, CV% 54.72 (13.75)
Residual variance, mg2 134.2 (8.07)
Abbreviations: aj, discrimination for item j; bj,inc, incremental difficulty for item 
j; bj,1, threshold difficulty for item j; CV, coefficient of variation; IRT, item 
response theory; LED, levodopa equivalent dose; LED0, initial LED; LEDmax, 
maximum LED allowed for prescription; r, rate of LED escalation; RSE, 
relative standard error; Snontrem, severity of nontremor symptoms; Strem, severity 
of tremor symptoms; UPDRS, Unified Parkinson's Disease Rating Scale.
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The predicted trajectories of the 
latent variables
To understand the possible cause behind the significant ef-
fects Strem and Snontrem have on the rate of LED changes, 
we used a subset of 36 patients who underwent additional 
UPDRS assessments of at least three consecutive UPDRS 
Part III scores to generate the expected time trajectories of 
the latent variables. Figure 4 shows the results.
Visual inspection suggests that the progression of Snontrem 
is faster than Strem, whereas the initial treatment responses 
are similar between Snontrem and Strem. To check for statistical 
significance, we binned the time intervals to pretreatment, 
0– 1 year, 1– 2 years, 2– 3 years, 3– 4 years, and 4 years and 
beyond. The difference of Snontrem between pretreatment 
(−0.097) and at 0– 1 year (−0.137) was not statistically sig-
nificant (p = 0.79). On the other hand, the difference of Strem 
at baseline (0.017) and 0– 1 year (−0.159) showed a signifi-
cant difference (p = 0.017). The difference of Snontrem between 
pretreatment (−0.097) and at 4 years and beyond (1.197) was 
highly significant (p = 3.22e- 05), whereas that of Strem was 
not (0.017 vs. 0.068; p = 0.73).
The previous results suggest that the initial treatment re-
sponse is greater for Strem than Snontrem, whereas the rate of 
progression is faster in Snontrem than Strem.
Simulation based on the web application
We developed a web application to facilitate the implemen-
tation of our model, which is hosted at https://dongy.shiny 
apps.io/parkin. The application takes individual UPDRS Part 
III scores as inputs and outputs the estimates of Snontrem and 
Strem, their uncertainty, and the longitudinal predictions of 
LED. The scores can be directly supplied through application 
widgets or a file in .csv format. For the latter, the file should 
abide by a specific format to be properly parsed by the ap-
plication. When a file consisting of serial UPDRS Part III 
assessments is uploaded, the application returns time series 
plots showing the changes of estimated Snontrem and Strem with 
time.
For illustrative purposes, three clinical scenarios were 
simulated using our web application. Figure  S5 shows the 
setup details of scenarios 1 and 3.
F I G U R E  2  (a) Observed LED time 
trajectories. Red line represents the median, 
and the colored band represents the 2.5th 
to 97.5th percentiles. Observed versus 
predicted LEDs of (b) model without 
covariate (Model 1), (c) model incorporating 
age only (Model 2), and (d) model 
incorporating both age and latent variables 
(Model 3). (e) The median and 2.5th to 
97.5th percentiles of observations (red) and 
predictions (blue) of Model 3 superimposed. 
LED, levodopa equivalent dose
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F I G U R E  3  Item response theory model evaluations. Mirror plots of (a) nontremor and (b) tremor items illustrate the high concordance 
between the proportions of the observed and simulated scores. (c) Scatterplot showing the concordance of the observed and median predicted 
proportions of scores. The red line is the line of identity
F I G U R E  4  The predicted time 
trajectories of Snontrem (left) and Strem (right) 
based on the estimated item response 
theory model parameters of 36 patients 
with at least three serial Unified Parkinson's 
Disease Rating Scale Part III assessments. 
The rate of progression was significantly 
faster in Snontrem than Strem. Snontrem, severity 
of nontremor symptoms; Strem, severity of 
tremor symptoms
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Scenario 1: a 60- year- old patient with a UPDRS Part III 
tremor subscore of 14 and a nontremor subscore of 18 
with a total score of 32 (tremor severity population per-
centile 83.66%, nontremor severity population percentile 
39.29%)
Scenario 2: an 80- year- old patient with the same UPDRS 
Part III item scores as Scenario 1
Scenario 3: a 60- year- old patient with a UPDRS Part 
III tremor subscore of 3 and a nontremor subscore of 29 
with a total score of 32 (tremor severity population per-
centile 49.31%, nontremor severity population percentile 
69.03%)
Total UPDRS Part III scores of all patients were identical 
(i.e., 32) at baseline assessment. However, the predicted LED 
requirements of Scenarios 1, 2, and 3 were 424, 590, and 
464 mg at baseline, and 807, 712, and 1127 mg, respectively, 
at 10 years after diagnosis (Figure S6).
A comparison of Scenarios 1 and 2 shows that given the 
same UPDRS Part III profiles, older age at initial diagno-
sis is associated with a higher initial LED but a slower rate 
of increase. Although Scenarios 1 and 3 have identical total 
UPDRS Part III scores, the predicted LED of Scenario 3 at 
10  years after diagnosis is nearly 50% greater than that of 
Scenario 1.
DISCUSSION
We developed a model that extracts two latent variables that 
represent tremor and non- tremor- related symptoms from 
baseline UPDRS Part III measurements to predict the changes 
of LED requirements with disease progression. Our results 
suggested that the rate of LED increase is significantly faster 
in patients with dominant rigidity and postural instability/gait 
disorder symptoms.
To our knowledge, this is the first modeling study that 
attempts to predict the changes of LED with disease progres-
sion using real- world data. Most previous studies concen-
trated on predicting disease progression based on changes of 
UPDRS.15 UPDRS assessment, however, is time- consuming 
and more suited to track disease progression in prospective 
clinical trials than in the clinician's office. LED, on the other 
hand, is easier to acquire.14
Levodopa is commonly initiated at doses 50 mg four times 
daily or 100 mg three times daily, depending on the presence 
of motor fluctuations and the risk of developing dyskinesia. 
In elderly patients aged older than 65 years, levodopa is often 
used as first- line therapy. In younger patients, dopamine ag-
onists are predominantly used and levodopa is initiated only 
when symptom control becomes insufficient, except in cases 
where patients show severe adverse effects with dopamine 
agonists.
In our data, the initial LED was indeed positively cor-
related with age. Moreover, initial LED showed significant 
positive associations with both total baseline UPDRS Part 
III and the estimated severity of nontremor symptoms, with 
the latter showing a higher significance level. The finding 
of nontremor severity being a better predictor of estimated 
initial LED than total UPDRS Part III score suggests that IRT 
offers an improved method of dose selection. Based on our 
results, tremor symptoms play a minor role in determining 
the LED in the initial stages of treatment.
The rate of LED increase was faster in patients with dom-
inant rigidity/bradykinesia, which is likely attributed to their 
faster disease progression as seen in Figure 4. However, the 
cause of differential progression rates between the two latent 
variables is uncertain. One possibility is that it is attributed 
to independent pathophysiological processes. Nevertheless, 
simulations based on our model suggest that the future LED 
trajectories diverge between patients with dominant rigidity/
bradykinesia and patients with dominant tremor given the 
same baseline total UPDRS Part III score. This highlights 
the importance of analyzing UPDRS at the item level and 
supports the practical utility of the IRT framework in dis-
tinguishing patients showing similar total UPDRS Part III 
scores.
The core assumption of our IRT model was that two la-
tent variables are sufficient to explain the totality of motor 
symptoms. We support this assumption based on both prior 
evidence and our data. First, a classification scheme of sub-
typing patients into either tremor dominant and postural in-
stability and gait disorder dominant subtypes is widely in use 
and has been validated across a number of studies.21 Second, 
analyses based on our data using principal components anal-
ysis showed that each of the first two principal components 
were highly correlated with nontremor and tremor items, re-
spectively, and hierarchical clustering of item scores gener-
ated the highest level division between nontremor and tremor 
items.
Our method is in many ways superior to categorizing pa-
tients into different motor subtypes. The greatest advantage is 
in resolving the problem of dealing with patients in the gray 
area. Although a separate category of “mixed” type has tradi-
tionally been used to define these patients, drawing clear de-
marcations between different subtypes is difficult. IRT does 
not categorize patients but instead returns independent num-
bers to represent the severity of each symptom dimension.
From a clinical standpoint, the discrimination of an item 
reflects its sensitivity to changes in the underlying disease 
process, and difficulty parameter the relative order of its 
first appearance. Although discriminations of all items were 
roughly similar, a greater variability was observed in the 
threshold difficulties. Our results suggest that disability of 
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pronation- supination movements of hands (item 25) and 
bradykinesia (item 31) appear relatively early during the 
disease time course, whereas postural instability (item 30) 
and difficulty rising from chair (item 27) constitute hall-
marks of late- stage PD. Among tremor, kinetic/postural 
tremor (item 21) would appear before resting tremor (item 
20). These interpretations fit well to that known from clin-
ical experience.
IRT is a complex modeling framework, which can under-
mine its widespread use despite its usefulness. Our web ap-
plication hides the technical details under the hood and only 
requires the users to input the UPDRS Part III measurements. 
The application then returns the recommended initial LED 
and its predicted increase with time. Furthermore, multiple 
assessments of UPDRS Part III scores can be fed into the 
application to acquire the time series plots of the estimated 
nontremor and tremor severities. We believe that these func-
tionalities would greatly reduce the barrier for the practicing 
physicians and encourage them to actually use our model.
The greatest limitation of our study is in the limited scope 
of disease severity collected from a relatively small number 
of patients. The item scores rarely reached their maximum 
values. This aspect should be taken into account when trying 
to extrapolate our model to a larger population consisting of 
the full range of possible disease states. The limited num-
ber of patients with repeated UPDRS Part III measurements 
probably also led to an insufficient power to detect correla-
tions between LED and UPDRS Part III changes. Finally, al-
though nonmotor symptoms constitute a critical portion of 
PD manifestation, our work did not analyze them.
Notwithstanding these limitations, our study results were 
mostly concordant with that known from previous reports. 
The severity of nontremor symptoms reached approximately 
1 standard deviation of the baseline severity by 50 months 
(see Figure  4), which is surprisingly close to that reported 
in a prior IRT- based study.8 The notion of negligible pro-
gression of tremor symptoms and the similar progression 
rates among the bradykinesia, rigidity, and gait and balance 
subscores are also supported by the literature.22 The relative 
order of threshold difficulties, when interpreted as coinciding 
with the relative order of symptom appearance with disease 
progression, also agreed with clinical experience and prior 
research.23
In conclusion, our study offers a novel method that al-
lows effective prediction of future LED requirements based 
on a one- time assessment of UDPRS part III scores. The web 
application that implements the developed model would sig-
nificantly add to the practical value of our work. The idea 
of using LED changes acquired from real- world data as an 
alternative disease progression marker, if validated through 
further studies, would open new ways to use the vast amount 
of observational data from electronic medical records. This 
would help acquire real- world evidence of disease progres-
sion and treatment effectiveness under a variety of clinical 
settings.
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